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ORIGINAL ARTICLE
Elevated calpain activity in acute myelogenous leukemia
correlates with decreased calpastatin expression
M Niapour
1, C Farr
1,2, M Minden
3 and SA Berger
1,2
Calpains are intracellular cysteine proteases that have crucial roles in many physiological and pathological processes. Elevated
calpain activity has been associated with many pathological states. Calpain inhibition can be protective or lethal depending
on the context. Previous work has shown that c-myc transformation regulates calpain activity by suppressing calpastatin, the
endogenous negative regulator of calpain. Here, we have investigated calpain activity in primary acute myelogenous leukemia
(AML) blast cells. Calpain activity was heterogeneous and greatly elevated over a wide range in AML blast cells, with no
correlation to FAB classiﬁcation. Activity was particularly elevated in the CD34þCD38  enriched fraction compared with the
CD34þCD38þ fraction. Treatment of the cells with the speciﬁc calpain inhibitor, PD150606, induced signiﬁcant apoptosis
in AML blast cells but not in normal equivalent cells. Sensitivity to calpain inhibition correlated with calpain activity and
preferentially targeted CD34þCD38  cells. There was no correlation between calpain activity and p-ERK levels, suggesting
the ras pathway may not be a major contributor to calpain activity in AML. A signiﬁcant negative correlation existed between
calpain activity and calpastatin, suggesting calpastatin is the major regulator of activity in these cells. Analysis of previously
published microarray data from a variety of AML patients demonstrated a signiﬁcant negative correlation between calpastatin
and c-myc expression. Patients who achieved a complete remission had signiﬁcantly lower calpain activity than those who had
no response to treatment. Taken together, these results demonstrate elevated calpain activity in AML, anti-leukemic activity of
calpain inhibition and prognostic potential of calpain activity measurement.
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INTRODUCTION
Acute myelogenous leukemia (AML), the most common acute
leukemia of adults, is a highly heterogenous disease, both at the
cellular and molecular levels. As many as 100 molecular or
cytogenetic alterations have been associated with AML
1,2 making
it one of the most diverse and challenging forms of human cancer.
Current standards of care can result in upwards of 50--75% of
adults achieving complete remissions (CRs) with therapies based
on nucleoside analogs, anthracyclines or topoisomerase inhibi-
tors.
3 However, only 20--30% typically have long-term, disease-
free survival.
3 There is thus a great need for improved therapies
and prognostic markers that can better predict outcome.
Calpains are intracellular, calcium-sensitive, neutral cysteine
proteases that have crucial roles in basic physiological and
pathological processes.
4- -7 Active calpains contain two sub-units;
a larger cysteine protease with catalytic activity and a smaller
regulatory subunit.
8 The two predominant members of the
calpain family, calpains 1 (m-calpain) and 2 (m-calpain), which
differ in their activation by Ca
2þ in vitro, have been extensively
studied.
9- -11 Calpain activity is subject to complex regulation.
Calpastatin, an endogenous calpain inhibitor, is one of the main
factors controlling calpain activity.
12- -18Previously, we demonstrated
that the c-myc oncogene regulates calpain activity by suppressing
expression of calpastatin. Thus, c-myc-transformed cells were
found to have low levels of calpastatin and highly elevated calpain
activity. Other identiﬁed regulators of calpain activity include
proteolysis, phospholipids, inhibition by protein kinase A through
phosphorylation of speciﬁc sites
4,19 and the microﬁlament-
associated protein GAS2.
20- -22 Calpain activity is also stimulated
by the ras pathway through mitogen-activated protein kinase
kinase (MEK-1/2) and Erk.
19,23- -27 Activation of the Ras-to-Mapk
(MAPK/Erk) signaling pathway, either directly through activating
RAS gene mutations or indirectly through other genetic aberra-
tions, has an important role in the molecular pathogenesis of
myeloid leukemia,
28- -35 suggesting that ras pathway activation
may be an important regulator of calpain activity.
Excessive calpain activation has been linked to a number of
pathological states, and calpain inhibitors can protect cells from a
variety of stress-inducing agents.
36- -39Paradoxically, calpain can also
be protective, particularly for transformed cells.
40- -45 Previously,
we observed that calpain activity in HL60 promyelocytic leukemia
cells was elevated compared with normal cord blood cells.
27
Functional experiments indicated that calpain inhibition induced
apoptosis in these cells.
46 As other protease inhibitors are
promising agents in the treatment of hematological disorders---
particularly myeloma and lymphoma,
47- -49 we have investigated
calpain activity in AML blast cells and sensitivity to calpain
inhibition. We have found that activity is greatly elevated and
varies over a wide range in AML blast cells. It is particularly
elevated in the CD34þCD38  enriched fraction compared with
the CD34þCD38þ fraction. Calpain activity did not correlate
with p-Erk levels but did correlate inversely with calpastatin
levels. Treatment with PD150606, the speciﬁc calpain inhibitor
induced apoptosis in AML blast cells but not normal cord blood.
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www.nature.com/bcjSensitivity to PD150606 correlated with calpain activity, suggest-
ing that calpain inhibition may have anti-leukemic activity. A
signiﬁcant negative correlation between calpastatin and c-myc
expression was observed in previously published microarray
data.
50 Calpain activity was signiﬁcantly lower in CD34þ cells of
patients who achieved CRs compared with those who had no
response to treatment (NR), suggesting calpain activity may have
prognostic signiﬁcance.
MATERIALS AND METHODS
Patient treatment and samples
Peripheral blood samples used in this study were obtained from newly
diagnosed, untreated patients. Samples were acquired during routine
patient evaluation and in accordance with institutional review at the
Princess Margaret Hospital. Patients who received induction therapy
received daunorubicin (60mg/m
2 per day) for days 1- -3 and cytarabine
(100mg/m
2 per day age 60- -80 years or 200mg/m
2 per day age 18- -59
years) for days 1- -7 by continuous infusion.
Flow cytometric analysis and calpain activity measurements
Sample preparation procedure was as described previously.
28 Brieﬂy, after
extraction of mononuclear cells from peripheral blood samples, cells were
stained with anti-CD45, anti-CD34 and anti-CD38 for 20min at room
temperature. After washing out the excess antibodies, calpain activity was
measured as described previously.
27 The calpain substrate dye, BOC-LM- -
CMAC,
51 was added to cell suspensions, where it diffuses readily into cells
and reacts with free thiols (that is, GSH) to enhance retention.
52 The cells
were ﬁxed after 1, 2, 5, and 10min by adding 0.5% paraformaldehyde. Cells
were kept overnight at 41C and were analyzed immediately or
permeabilized by methanol and Saponin solution for additional intracel-
lular staining. The cells were washed two times, anti-pErk was added
and kept on ice for 20min. The cells were washed and resuspended in
phosphate-buffered saline with 2% fetal bovine serum and analysed with
the LSR II (Becton Dickinson, Mississauga, ON, Canada), which was
calibrated by standard beads before each experiment. The staining and
ﬂow cytometric analysis are shown in Figure 1.
Apoptosis assay
Mononuclear cells were incubated with the calpain inhibitor PD150606
(100mM) overnight. Cells were stained with anti CD45, CD34 and CD38 as
described above. Apoptosis was measured by annexin V and PI staining.
Limiting dilution assay
Cells were washed twice with serum-free RPMI 1640 and treated with
100mM PD150606 overnight. After washing with fresh medium containing
10% fetal bovine serum, cells were adjusted to a cell density of 1 10
6/ml.
A total of 10 serial ﬁvefold dilutions were made from these suspensions.
In all, 100ml of each dilution was added to six wells of a 96-well plate,
each containing 100ml of RPMI supplemented with 10% fetal bovine
serum. The diluted cells were cultured for 10 days at 371Ci n5 %C O 2.
Calculation of the number of viable units per well was based on the
Spearman’s estimator.
Statistical analysis
Student’s t-test or ANOVA was used to evaluate the signiﬁcance of
differences between groups. Results are reported as the mean±s.e.m.
*Po0.05, **Po0.01.
RESULTS
Calpain activity is variable in different subpopulations of AML
samples
We previously observed that calpain activity was elevated in HL60
promyelocytic leukemia cells
27 and that these cells were sensitive
to calpain inhibition.
46 These observations prompted us to
investigate calpain activity in primary AML samples. Peripheral
blood samples obtained from recently diagnosed patients with
AML were taken from unselected, sequential patients. Table 1
summarizes the FAB classiﬁcation, cytogenetics and clinical
responses of the patients to date. Samples were stained for
CD45, CD34, CD38, p-Erk, calpastatin and calpain activity was also
measured. Mean calpain activity was 0.228 DF/DTs
 1 in
CD34þCD38þ cells with a standard deviation of 0.147
(Figure 2a). In the CD34þCD38  population mean calpain
activity was 0.356 DF/DTs
 1 with a standard deviation of 0.141
(Figure 2a), which is 75% higher than calpain activity in HL-60 cells
and 13.8, 4.1, and 6.7-fold higher than calpain activity in
lymphocytes, monocytes and granulocytes of cord blood,
respectively.
27 Mean calpain activity in the CD34þCD38 
population was signiﬁcantly higher than CD34þCD38þ activity
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Figure 1. Flow cytometric analysis of cell surface, intracellular
markers and calpain activity in AML peripheral blood samples.
(a) SSC/CD45---the AML cells were stained as described in the
Methods section with FITC mouse anti-human CD45, APC mouse
anti-human CD34 and PE mouse anti-human CD38. The FITC
and side scatter proﬁle was used to gate on the AML blast cells
(population with 91.6% of cells in ﬁgure). (b) CD34/CD38  after
gating on the blast cells, CD34 and CD38 expression was examined
by APC and PE co-staining. Four populations were present, and
the CD34þCD34þ and CD34þCD38  subsets were determined
based on the ﬂuorescence of unstained controls. (c) t-BOC-CMAC---
shown is a representative histogram for the ﬂuorescence change
in the product of the calpain assay over the course of the
experiment. 1, 2, 5 and 10min were the timepoints used for analysis.
(d) p-ERK---shown is a representative histogram for p-ERK staining.
Left shows the unstained control. Right is the stained blast cells.
(e) Calpastatin---shown is a representative histogram for calpastatin
staining. Left shows the unstained control. Right is the stained
blast cells.
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Blood Cancer Journal & 2012 Macmillan Publishers Limited(Figure 2a). Furthermore, although the majority of samples had
higher activity in the CD34þCD38  fraction, 19% of the samples
had higher activity in the CD34þCD38þ fraction. We conclude
that in AML, calpain activity is very high and heterogeneity of
activity is apparent.
AML is conventionally classiﬁed according to the FAB classiﬁca-
tion system that takes into account type of cell from which the
leukemia developed and its level of differentiation. As shown in
Figure 3, we observed wide variation in calpain activity that did
not correlate with FAB classiﬁcation in either the CD34þCD38 
or CD34þCD38þ fractions. These observations suggest that the
phenotypic characteristics of FAB types do not reﬂect calpain
activity variation.
p-Erk and calpain activity
Elevation of p-Erk in AML has been previously demonstrated,
suggesting common activation of the ras pathway.
32- -34 Further-
more, as previously demonstrated,
27 the ras pathway is an
important regulator of calpain activity. We therefore investigated
the relationship between pErk levels as an indicator of ras
pathway activation and calpain activity. As shown in Figure 4, our
results indicate that CD34þCD38  cells exhibit a signiﬁcantly
higher mean level of p-Erk compared with CD34þCD38þ cells.
Furthermore, as with calpain activity itself, whereas the majority of
samples had higher p-Erk staining in the CD34þCD38  fraction,
30% of the samples had higher p-Erk staining in the
CD34þCD38þ fraction. There did not appear to be any
correlation of these samples with FAB classiﬁcation. When p-Erk
was plotted against calpain activity it was apparent that no
particular correlation was observed between the two measure-
ments for either the CD34þCD38  or CD34þCD38þ fractions
(Figures 4c and d). This observation suggests that the ras pathway,
as measured by p-Erk levels, may not be a major driver of calpain
activity variation in AML.
Calpastatin and calpain activity
Calpain activity is strongly regulated by the endogenous inhibitor
calpastatin. Calpastatin binds with a stoichiometry of 1:4 to
inactivate calpains and is considered one of the major regulators
of calpain. We therefore measured calpastatin levels in the AML
blast cell samples. As shown in Figure 5a, calpastatin levels in
the CD34þCD38  fraction were signiﬁcantly lower than in
the CD34þCD38þ fraction. Higher calpastatin levels in the
CD34þCD38þ fraction were observed in every sample except
two. The decreased calpastatin levels in the CD34þCD38 
fraction correspond to the increased levels of calpain activity in
this fraction. This was conﬁrmed by plotting calpain activity vs
calpastatin levels. As shown in Figures 5c and d, we observed a
signiﬁcant negative correlation between calpain activity and
calpastatin levels in both the CD34þCD38  and CD34þCD38þ
fractions. These observations therefore suggest that calpastatin
variation contributes signiﬁcantly to calpain activity variation.
Sensitivity of AML cells to apoptosis induced by PD150606
The observed elevated level of calpain activity in the AML samples
suggests that they may also be sensitive to calpain inhibition. We
therefore tested sensitivity of some of the samples to the calpain
inhibitor PD150606.
53 PD150606 is an alpha-mercaptoacrylic acid
derivative that was ﬁrst identiﬁed and characterized by Wang
et al.
53 We used this compound for calpain inhibition in our in vitro
assays, as it is highly speciﬁc for calpain as opposed to cathepsins,
papain, trypsin or thermolysin.
53 Although it is speciﬁc, it has
relatively low potency in vitro. We previously reported that its Ki in
Table 1. Cytogenetics, FAB classiﬁcation and clinical status of some of
the AML patients
Patient Cytogenetics FAB
classiﬁcation
Response
0049 46XY M4 No tx
0063 46XX M1 CR to relapse
0068 46XX M0 CR to relapse
0128 47XY+13 M5 No tx
0129 MDS No tx
0133 NA AML No tx
0136 46XX-20 AML Early death
0156 46XX M4 CR
0161 46XY M2 No tx
9505 47 XY +8 M2 NR
9506 50 XX+13+14+20+22 M0 No tx
9526 XX 18p/0 M1 No tx
9566 XX M4 CR
9626 NA M1 No tx
9632 M2 No tx
9635 Inv 16 M4eo CR
9642 Inv 16 M4eo CR
9757 47XY+11, 47XY+8 M4 No response
9805 46XX M5a CR
9822 NA M1 No tx
9824 46XYdel(20)(q11q13) M4 CR
9827 46XX AML No response
9833 47-48XY
del(5)(q13q31)i(19)(q10)
del(20)(q11q13)+mar+mar
M1 Early death
Abbreviations: AML, acute myelogenous leukemia; CR, complete remission;
MDS, myelodysplastic syndrome; NR, no response; tx, treatment.
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Figure 2. Calpain Activity in CD34þCD38  and CD34þCD38þ
fractions of AML samples. (a) Comparison of calpain activity in
CD34þCD38  vs CD34þCD38þ cells. (b) Pairing of calpain
activity for each sample.
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27 We have also observed that PD150606
becomes inactivated over time when dissolved in aqueous
medium with an inactivation half life of 12h.
46 We therefore used
the concentration of 100mM to test sensitivity to the drug. Cells
were exposed to PD150606 overnight and cell death was
measured by apoptosis assay or limiting dilution assay as
described by Soboloff et al.
54 Cells were treated with PD150606
and serially diluted cells were plated in 96-well plates for 10 days.
Wells with cell growth were scored and viable cells were
estimated based on the Spearman’s estimator for serial dilution
assays. The limiting dilution assay indicated a log reduction in cell
viability between 2.8 and 5.7 for cells treated with PD150606.
The level of apoptosis was observed to be signiﬁcantly higher
in CD34þCD38  cells (average: 58%) compared with
CD34þCD38þ cells (average 30%) (Figure 6a). In comparison,
PD150606 treatment of normal cord blood resulted in 4.25% and
4.1% apoptosis of CD34þCD38  and CD34þCD38þ cells,
respectively (Figure 6a). Furthermore, we observed a signiﬁcant
correlation between apoptosis in the CD34þCD38  population
and log reduction by limiting dilution (Figure 6b). There also
appears to be a trend towards increased apoptosis induction
by PD150606 with increased calpain activity (Figures 6c and d).
These results suggest that calpain activity may be an important
biomarker of disease and that calpain inhibition preferentially
targets CD34þCD38  cells in AML.
Calpain activity and patient outcome
We investigated whether calpain activity correlated with patient
response to treatment. Additional patient samples for which
outcomes were known, were obtained from a sample bank to
ensure sufﬁcient statistical power. Data regarding patient outcome
were obtained when available, and we examined if there was a
difference in calpain activity between those patients who
achieved CRs and those who had NR. When the CD34þ cells
were analyzed, calpain activity was found to be signiﬁcantly lower
in those patients who underwent CR (Figure 7a). When the blast
cells were further analyzed based on CD34 and CD38 expres-
sion, no signiﬁcant difference was seen between NR and CR
in the CD34þCD38  subset (Figure 7b). However, in the
CD34þCD38þ subset, calpain activity is signiﬁcantly lower in
those patients who underwent CR (Figure 7c). These results
suggest that calpain activity may have prognostic relevance.
Those patients with lower calpain activity in CD34þ blast cells
were more likely to undergo CR compared with those with higher
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Figure 4. pErk expression in CD34þCD38  and CD34þCD38þ
fractions of AML samples. (a) Comparison of pErk staining in
CD34þCD38  vs CD34þCD38þ cells. (b) Pairing of pErk staining
for each sample. (c) Plot of calpain activity vs pErk staining for
CD34þCD38  cells. (d) Plot of calpain activity vs pErk staining for
CD34þCD38þ cells. In both (c) and (d), the curve represents a
least-squares ﬁt of a linear relationship between the variables, as
calculated by the Prism software.
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Figure 5. Calpastatin expression in CD34þCD38  and
CD34þCD38þ fractions of AML samples. (a) Comparison of
calpastatin staining in CD34þCD38  vs CD34þCD38þ cells.
(b) Pairing of calpastatin staining for each sample. (c) Plot of calpain
activity vs pErk staining for CD34þCD38  cells. (d) Plot of calpain
activity vs pErk staining for CD34þCD38þ cells. In both (c) and
(d), the curve represents a least-squares ﬁt of a linear relationship
between the variables, as calculated by the Prism software.
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Figure 3. Calpain activity and FAB classiﬁcation of AML samples.
(a) Calpain activity of CD34þCD38  cells grouped by FAB
classiﬁcation. (b) Calpain activity of CD34þCD38þ cells grouped
by FAB classiﬁcation.
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Blood Cancer Journal & 2012 Macmillan Publishers Limitedactivity. It is of note that the patient with the highest calpain
activity in the CR group rapidly relapsed following induction of
remission. As this patient relapsed rapidly, the sample was not
included in statistical calculations. It would be of interest to
monitor those patients who achieved CR to determine if there is a
correlation between calpain activity and time until relapse.
DISCUSSION
AML is the most common acute leukemia in adults and one of the
most challenging to treat. As advanced chemotherapy can induce
remission in 70--80% of patients, most will relapse, emphasizing
the need for new therapies and better prognostic approaches that
can predict outcome and direct treatment. Here, we have
investigated calpain activity and sensitivity to calpain inhibition
in AML blast cells. We have observed wide variation in activity,
with higher activity in the CD34þCD38  fraction compared with
the CD34þCD38þ fraction. We have also observed an inverse
correlation between calpain activity and the endogenous inhibitor
calpastatin, but no correlation with p-Erk levels, suggesting that
calpastatin but not the ras pathway, is a major contributor to
calpain activity variation in AML blast cells. We also observed
signiﬁcant sensitivity of AML blast cells to the calpain inhibitor
PD150606, both by apoptosis induction and limiting dilution
assay. Furthermore, this sensitivity correlated with calpain activity
levels, particularly in the CD34þCD38  fraction. Calpain activity
did not correlate with any particular FAB classiﬁcation. However,
we observed that calpain activity in CD34þ cells and particularly
in the CD34þ CD38þ subset as measured at diagnosis was
low in those patients who achieved CR and higher in those who
had NR. Taken together, these observations indicate that calpain
activity may have prognostic value and calpain inhibition may be
useful as part of an anti-leukemic strategy.
Previously, we demonstrated that c-myc regulates calpain
activity by negatively regulating calpastatin. Thus, c-myc-negative
cells had high levels of calpastatin and low calpain activity, while
c-myc-transformed cells had low calpastatin levels and very high
activity.
46 Furthermore, knockdown of calpastatin in c-myc-negative
cells was found to restore calpain activity, promote anchorage-
independent growth and tumorigenicity. These observations
therefore suggest that calpain activity is an effector of c-myc’s
transforming activity. Our observation of an inverse correlation
of calpastatin levels with calpain activity in the current study is
consistent with calpastatin being the major regulator of activity
and may reﬂect the variability of c-myc function in these cells.
In support of this possibility, an analysis of gene expression data
obtained from the work of Gutie ´rrez et al.
50 shows a highly signiﬁ-
cant inverse correlation between calpastatin and c-myc expression
obtained from a variety of AML samples (Supplementary Figure 1).
Our observations do not address the mechanism by which
calpain promotes c-myc transformation. However, calpains are
known to target cell cycle-related proteins such as CDKs.
55- -58
As well, Kindle et al.
59 have shown that calpain is essential
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Figure 7. Calpain activity and clinical response of AML samples.
(a) Calpain activity of CD34þ cells grouped by clinical response.
(b) Calpain activity of CD34þCD38  cells grouped by clinical
response. (c) Calpain activity of CD34þCD38þ cells grouped by
clinical response. NR, no response, CR, complete remission.
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Figure 6. Apoptosis and loss of viability induced by calpain inhibitor
PD150606 in CD34þCD38  and CD34þCD38þ enriched fractions
of AML samples. (a) Comparison of apoptosis induction in
CD34þCD38  vs CD34þCD38þ cells by PD150606. Cells were
exposed to 100mM PD150606 o/n. Cells were scored for apoptosis
using annexin V and PI staining. Open squares are measured levels
of apoptosis in cord blood-derived cells. (b) Correlation between log
reduction in viability and apoptosis induction in CD34þCD38 
cells exposed to PD150606. Apoptosis was as determined in part (a).
To determine reduction in viability, cells were exposed to 100mM
PD150606 o/n, collected and then analysed by limiting dilution
analysis as described in Materials and methods. (c) Plot of %
apoptosis vs calpain activity in CD34þCD38  cells. Apoptosis is
described in part (a). Calpain activity is as reported in Figure 2.
(d) Plot of % apoptosis vs calpain activity in CD34þCD38þ cells.
Apoptosis is described in part (a). Calpain activity is as reported
in Figure 2. In both (c) and (d), the curve represents a least-squares
ﬁt of a linear relationship between the variables, as calculated
by the Prism software.
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that are essential for MOZ-TIF2-mediated transformation in AML.
Such proteins may therefore be important targets in AML.
While early pioneering experiments suggested that leukemic
stem cells resided primarily in the CD34þ CD38  fraction,
60,61
subsequent experiments have shown that in some cases,
other fractions can also contain LSCs.
62 Nevertheless, the
CD34þ CD38  fraction is thought to be enriched in LSCs.
Clearly, calpastatin expression and consequently calpain activity
distinguished strongly between the CD34þCD38  and
CD34þCD38þ fractions. These differences may also represent
differential c-myc activity and thus may be related to their
respective leukemic potential.
The close connection between c-myc, capastatin and calpain
activity suggests that loss of calpastatin activity may have tumor-
promoting activity, and thus calpastatin may have tumor
suppressor function, particularly in cells that do not have excessive
levels of c-myc. In fact it is of interest to note that CAST, the
calpastatin gene is located on chr 5q15,
63 which is frequently lost
in 5q- syndrome.
64 Consistent with this possibility, we note that
the sample with the highest measured calpain activity had a
classic 5q- deletion.
We do not yet know how calpain inhibition targets transformed
cells; however, our previous results suggest that c-myc is a major
sensitivity factor. Given the extensive involvement of c-myc in
AML and other leukemias and lymphomas, it is possible that
c-myc is also a major driver of sensitivity in AML. In support of this
model, we have found that lymphomas derived from Em-myc
transgenic mice have decreased calpastatin levels, elevated
calpain activity and sensitivity to calpain inhibition (Li et al.;
submitted). In this model, apoptosis induction through calpain
inhibition was found to be dependent on caspase 3 activation but
independent of caspase 9, suggesting a mechanism independent
of classical mitochondrial apoptosis. Future work will be required
to better deﬁne this pathway in lymphoma and AML.
Patients who experienced CRs had signiﬁcantly lower calpain
activity than patients who did not respond to treatment. This was
particularly evident in the CD34þCD38þ fraction. While hetero-
geneous, the majority of CD34þ cells were CD38þ. It is therefore
not surprising that the ability to induce remission is primarily
dependent on this fraction. Long-term outcomes, however, would
be more dependent on cell fractions with extensive self-renewing
potential. Therefore, it will be of great interest to examine relapse
and long-term survival in the context of calpain activity.
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